Your oncologist is treating the cancer, but who’s tracking the metabolic fire that may be feeding it?
If you or someone you love is fighting cancer, that question matters more than most people realize. Oncologists monitor basic labs to watch for treatment side effects, but there’s a much bigger picture that often goes unseen: the metabolic conditions that can drive cancer progression, blunt treatment response, or set the stage for recurrence after remission. And most patients never receive the critical labs that could change everything. The vast majority of oncologists are simply not ordering them.
Cancer does not exist in a vacuum. It thrives within a metabolic environment that either supports or resists its growth. Insulin resistance, chronic inflammation, oxidative stress, acidity of the interstitial fluid, hormonal imbalances, and nutritional deficiencies are not background noise. They are the conditions that feed the fire. And the vast majority of cancer patients have never had them properly tested or interpreted. Think of it like trying to put out a campfire while someone keeps throwing gasoline on it. Until you remove the fuel, the fire will return.
The danger of omitting these labs is not theoretical. When these metabolic drivers go unmeasured, they go unmanaged. And when they go unmanaged, patients in active treatment may be fighting the disease with one hand while their own metabolism fuels it with the other, and patients who believe they are in remission may be walking around in a body that is still metabolically primed for recurrence. Whether the cancer is being actively treated or has been declared gone, the conditions that support its growth remain fully intact and unchallenged if no one is looking for them.
I recently reviewed labs for a patient whose oncologist had declared her in remission. Her standard bloodwork looked fine. But her fasting insulin was 22 uIU/mL, her hs-CRP was elevated at 4.8 mg/L, her vitamin D was 24 ng/mL, and her neutrophil-to-lymphocyte ratio was 4.1. She was metabolically still feeding the fire, and no one had told her. Her case is not unusual. It is, in my experience, the norm.
Cancer as a Metabolic Disease: The Terrain Before the Tumor
For nearly a century, researchers have recognized that cancer cells handle energy and nutrients differently than healthy cells. The observation dates to the 1920s, when Otto Warburg noticed that cancer cells burn glucose in an unusual way, producing large amounts of lactate even when plenty of oxygen is available. This pattern is so distinctive that it still bears his name today, the Warburg effect. Warburg’s insight was largely pushed aside during the decades when cancer research focused almost exclusively on genetic mutations, but it has come roaring back over the last fifteen years. Cancer has been called a “metabolic disease,” and for good reason. A growing body of work, led most visibly by Thomas Seyfried, PhD, at Boston College, now views cancer fundamentally as a disorder of how cells produce energy and handle nutrients, with genetic mutations serving more as facilitators than as first causes. Struggling mitochondria, disordered nutrient signaling, and the loss of metabolic flexibility do not just come along for the ride during cancer development. They help set the stage for it.
This framing has direct consequences for how we think about the labs described in the rest of this article. Cancer and cardiometabolic diseases often travel along the same highway, driven by the same underlying metabolic problems and branching off at different exits depending on a person’s genetics, tissue vulnerabilities, and lifetime exposures. The same biomarkers that predict cardiovascular disease and type 2 diabetes, including fasting insulin and HOMA-IR, hemoglobin A1c, the triglyceride-to-HDL ratio, high-sensitivity C-reactive protein, fasting glucose, apolipoprotein B, oxidized LDL, the neutrophil-to-lymphocyte ratio, and waist circumference, also help predict cancer risk, death from cancer, and how likely an existing cancer is to resist treatment. Chronically high insulin acts as a steady growth signal through the IGF-1 axis. Elevated blood sugar preferentially feeds the kind of energy metabolism cancer cells favor. Widespread inflammation, reflected by a high hs-CRP and a rising neutrophil-to-lymphocyte ratio, creates the same pro-cancer environment throughout the body that tumors build around themselves locally. Oxidized LDL reflects ongoing damage to DNA, proteins, and fats, the kind of damage that helps start cancer in the first place and helps it resist treatment once established. Abnormal cholesterol patterns change the supply of fatty acids that cancer cells use for fuel. And visceral fat, the fat stored deep around your organs, behaves like an active hormone-producing organ, releasing inflammatory chemicals and extra estrogens that pour into the same hostile internal environment.
When these biomarkers drift out of their optimal range, your own body begins to resemble, in miniature, the conditions that make established tumors so hard to treat. A body marked by insulin resistance, chronic low-grade inflammation, oxidative stress, and struggling mitochondria is a body in which the supportive environment for cancer is already partially built. Cancer cells that arise in this setting do not have to build a hostile neighborhood from scratch. They inherit one. And for patients who already have cancer, those same out-of-range numbers can blunt the effectiveness of chemotherapy, radiation, and immunotherapy by keeping alive the very inflammatory, insulin-driven, oxidatively stressed conditions that cancer cells exploit to adapt and survive. Normalizing these biomarkers is therefore not a soft, preventive afterthought. In patients with active disease, it is part of the treatment itself, pulling the rug out from under the metabolic program that drives cancer forward and restoring conditions under which both your immune system and your conventional therapies can do their work. In patients who have completed treatment and been told they are in remission, it is how you keep the fire from reigniting, because the same metabolic conditions that supported the original cancer are the conditions under which a recurrence would take hold.
Glucose Metabolism Markers
Cancer’s primary fuel source is glucose. Fasting glucose, hemoglobin A1c, fasting insulin, and 1,5-anhydroglucitol (GlycoMark) together reveal the degree to which your body’s glucose regulation is feeding tumor growth. Research consistently shows that cancer patients often have severe insulin resistance comparable to type 2 diabetes. In a large-scale analysis published in the Journal of Clinical Oncology, breast cancer patients with fasting insulin levels in the highest quartile had a 2.1-fold increased risk of recurrence and a nearly threefold increase in mortality compared to those in the lowest quartile. Standard glucose tests alone miss early insulin resistance, the very condition that drives so much of the downstream damage. GlycoMark detects glucose spikes that A1c misses entirely, spikes that cause direct vascular damage and oxidative stress throughout the body. By combining all four markers, we construct a complete picture of glucose metabolism at its earliest and most actionable stage.
IGF-1
Insulin-like growth factor 1 is one of the most potent growth signals in the body. It tells cells to grow and multiply while preventing natural cell death, both of which are deeply problematic when cancer cells are present. High animal protein intake elevates IGF-1, and higher levels are consistently linked to increased risk of several cancers, including breast, prostate, and colorectal cancer. Careful interpretation matters here because IGF-1 also plays an important role in maintaining healthy tissues. Too low, and you lose muscle mass, bone density, and tissue repair capacity. Too high, and you are pressing the accelerator on cellular growth in a body that may already be struggling to keep abnormal cells in check. Finding the right balance requires testing, not guessing.
Inflammatory Markers
Chronic inflammation fuels cancer. High-sensitivity C-reactive protein (hs-CRP) and homocysteine measure cancer-promoting inflammation in your body. Elevated hs-CRP is one of the strongest independent predictors of both cardiovascular events and the kind of systemic inflammation that promotes tumor growth. In multiple large cohort studies, patients with hs-CRP levels above 3.0 mg/L have been shown to have significantly higher rates of cancer progression and shorter overall survival across several tumor types. Homocysteine signals dysfunction in the methylation pathways critical to DNA repair and detoxification. Addressing elevated inflammation can help create an internal environment far less favorable to tumor growth, invasion, and metastasis. The good news is that elevated homocysteine is often correctable with targeted B-vitamin supplementation.
Neutrophil-to-Lymphocyte Ratio
This simple calculation from your complete blood count is one of the most powerful and inexpensive prognostic markers in oncology. A meta-analysis of over 100 studies encompassing more than 40,000 patients found that an elevated NLR was associated with significantly worse overall survival across virtually every solid tumor type. Here is what most patients do not realize: this number is already on your standard bloodwork. It just needs to be calculated and interpreted in the context of your cancer. Your oncologist has this data in hand at every visit. It is simply not being used. An elevated platelet count, meanwhile, can signal chronic inflammatory states that promote both tumor growth and the systemic deterioration that undermines your body’s ability to fight.
Lipids: Apolipoprotein B, Oxidized LDL, and Triglyceride-to-HDL Ratio
Standard cholesterol panels report LDL as a concentration, but what actually matters is the number of particles carrying that cholesterol. Apolipoprotein B (ApoB) is the direct measure of that count. Every atherogenic lipoprotein particle carries exactly one ApoB molecule, making ApoB the single most accurate measure of how many potentially harmful particles are in circulation. Two patients with identical LDL cholesterol levels can have dramatically different particle counts, and the patient with more particles carries the greater risk. Elevated ApoB levels drive chronic low-grade inflammation, impair microvascular function, and deliver lipid building blocks directly to tumor cells, which upregulate their LDL receptors to fuel rapid growth. But quantity is only half the story.
Oxidized LDL tells you how many of those particles have been damaged by oxidative stress. Once oxidized, these particles activate inflammatory signaling in tissue macrophages, degrade the protective lining of capillaries, and damage cellular DNA throughout the body, thereby contributing to the accumulation of mutations that initiate cancer and to the development of treatment resistance in existing cancers.
The triglyceride-to-HDL ratio adds a third dimension to this picture. A high ratio basically means you have too much fat circulating in the blood and not enough HDL, the “protective” cholesterol that helps clean up inflammation and oxidative damage, and this combination creates a metabolic environment that makes cancer more likely to grow. When triglycerides are high, your body is usually dealing with insulin resistance, higher estrogen activity, and more inflammatory signals, all of which can push cells toward abnormal growth. When HDL is low, you lose a major antioxidant and anti-inflammatory defense system that normally helps protect DNA from damage. Together, a high TG/HDL ratio reflects chronic inflammation, oxidative stress, hormonal imbalance, and poor metabolic health, and studies link this pattern to an increased risk of several cancers. In simple terms, the higher the triglycerides and the lower the HDL, the more fertile the internal environment becomes for cancer to develop or progress.
Together, ApoB, oxidized LDL, and the TG/HDL ratio reveal whether the cholesterol in your blood is not only excessive in quantity but actively damaging your cellular machinery and sitting inside a metabolic pattern that favors cancer growth, a combination that standard lipid panels miss entirely.
Iron and Copper
Elevated ferritin (iron) and ceruloplasmin (copper) create a pro-cancer environment. Cancer cells have an increased demand for iron, and excess iron is a potent pro-oxidant that generates free radicals through the Fenton reaction, directly damaging DNA and cellular structures. In practical terms, this means that if your ferritin is chronically elevated, your body is generating ongoing oxidative damage that promotes the very mutations and cellular instability that drive cancer forward. Copper plays a critical role in angiogenesis, the formation of new blood vessels that tumors need to grow and spread. Without an adequate blood supply, a tumor cannot grow beyond the size of a pinhead. Elevated copper helps it build the infrastructure it needs. Both deficiency and excess are harmful. Iron deficiency impairs oxygen delivery and exercise capacity. Iron overload induces oxidative damage to cellular structures. Only testing reveals where you stand, and only optimal-range interpretation tells you what to do about it.
Coagulation Markers
Elevated D-dimer and fibrinogen activity can drive cancer progression and treatment resistance. Cancer creates a hypercoagulable state that facilitates metastasis. Most doctors order coagulation tests only when a patient presents with a clotting event, but chronically elevated levels in otherwise stable patients are powerful predictors of future cardiovascular events, stroke, and cancer-related outcomes. What many patients do not realize is that the coagulation system is not a passive bystander in cancer. Many tumors actively exploit it. Fibrin deposits physically shield circulating tumor cells from immune detection, and elevated D-dimer levels have been independently associated with shorter survival in patients with advanced cancers. These markers reveal whether your clotting system is being recruited by the disease as an accomplice.
Thyroid and Cortisol
Low thyroid function and chronically elevated cortisol are two overlooked metabolic drivers that can quietly accelerate cancer by shaping the internal terrain in its favor. Low thyroid levels slow cellular metabolism, weaken immune surveillance, and increase systemic inflammation, which is the same inflammatory environment that can fuel tumor growth. This is why assessing thyroid status with a Free T3-to-Reverse T3 ratio, rather than relying on TSH alone, is so important. The ratio reflects how much active thyroid hormone your cells actually receive and gives a far better picture of whether your metabolic engine is running efficiently or stuck in low gear. Excess cortisol adds another layer of metabolic stress by suppressing immune activity, raising blood sugar and insulin, and increasing oxidative damage, which amplifies the very conditions, such as insulin resistance, inflammation, oxidative stress, and acidic interstitial chemistry, that cancer cells exploit to grow, invade, and resist treatment. Together, low thyroid and high cortisol do not cause cancer by themselves, but they create a biological landscape in which cancer spreads more easily, and therapies have to work harder to succeed.
Vitamins B12 & D
High vitamin B12 levels from excess supplementation can push the body into a state where cell growth signals become louder than they should be, and certain cancers are very good at taking advantage of that extra fuel. When B12 is far above normal, it can overstimulate methylation pathways, which are the chemical switches that help control which genes stay quiet and which genes stay active, and this can accidentally strengthen growth programs that cancer cells already rely on. Very high B12 can also raise the proteins that carry B12 through the bloodstream, and these proteins are often elevated in people with active tumors because cancer cells use them to support rapid division. The overall effect is not that B12 creates cancer out of nowhere, but that unusually high levels can make it easier for an existing or developing cancer to grow, survive, and spread by giving it more of the raw materials it prefers.
Low vitamin D is associated with worse cancer outcomes across multiple cancer types. This is one of the most correctable deficiencies in medicine, yet it is often not monitored during cancer treatment. Vitamin D functions as a hormone that influences immune regulation, cardiovascular protection, and cancer prevention. Vitamin D receptors are present throughout the body, and optimal levels support the immune surveillance systems that recognize and eliminate abnormal cells. The “normal” range for vitamin D extends down to 30 ng/mL, a level at which immune impairment and poor outcomes are already well documented. A pooled analysis of prospective studies found that patients with vitamin D levels below 20 ng/mL had a 30 to 50 percent higher cancer-specific mortality compared to those with levels above 40 ng/mL. Optimal is not the same as normal.
Urine pH
This test provides valuable insight into the acid-base balance of your body’s internal terrain. Urine pH parallels the acidity of the interstitial fluid, the fluid surrounding every cell, including the tumor, because the kidneys adjust urine in direct response to the acid-base conditions they detect in that space. The tumor microenvironment is typically acidic, which protects tumors from immune attack, promotes invasion and metastasis, contributes to treatment resistance, and supports the survival of cancer stem cells that drive recurrence. While urine pH is not a direct measurement of tissue-level acidity, consistently acidic readings reflect dietary and metabolic patterns that create an unfavorable environment for healing.
Why Optimal Ranges Matter
Perhaps the most important distinction in all of this is the difference between “normal” and “optimal.” Standard reference ranges are derived from population averages that include large numbers of people who are already metabolically unhealthy. Falling within the “normal” range often means only that you are no sicker than the average American, a bar that is disturbingly low. Optimal ranges are based on published research and clinical experience that identifies the levels associated with the lowest disease risk and the best functional outcomes. A fasting insulin level of 20 uIU/mL is technically “normal” by most lab standards, but it reflects a degree of insulin resistance that substantially fuels the metabolic environment in which cancer thrives.
Where This Leaves You
If you have read this far, you already understand something that most cancer patients never learn: the standard oncology panel is not enough. The metabolic conditions that fuel cancer progression, blunt treatment response, and set the stage for recurrence are measurable and, in most cases, correctable. But they can only be corrected if someone is looking for them.
Ask your oncologist if these markers can be added to your next blood draw. Some will be willing, and that is a great place to start. But in my experience, most oncologists are focused on tumor-directed treatment and are either unfamiliar with these markers, unable to order them within their system, or unsure how to interpret them in the context of cancer biology. If that describes your situation, you are not alone, and you do not have to wait.
What Progress Looks Like
What patients consistently describe once these metabolic markers begin moving into their optimal ranges is not a single dramatic moment but a quiet return of things they had forgotten were missing. Energy comes back first in small increments, then in ways that family members often notice before the patient does. The low-grade inflammation eases, and with it the aches, the mental fog, and the persistent sense that the body is working against itself. Sleep deepens. Body composition shifts in the direction it is supposed to shift. Fasting insulin drops. Hs-CRP falls. The neutrophil-to-lymphocyte ratio comes down. Vitamin D climbs into the range where immune surveillance actually works. These changes rarely happen all at once, but when you track them over three to six months of targeted intervention, the trajectory is unmistakable. Perhaps the most meaningful change, though, is not a number on a lab report. It is the shift in how patients experience their own disease. They stop feeling like passengers in a process being done to them and start feeling like active participants in a plan they understand and can influence. That shift, from passive recipient to engaged participant, is often as therapeutic as any single intervention on the protocol.
Stop Feeding the Fire. Take the Next Step Today.
Every day these metabolic imbalances go undetected is another day your body’s internal environment is working for the cancer instead of against it. And the question of timing is not abstract. For patients in active treatment, every cycle of chemotherapy, radiation, or immunotherapy that proceeds in an unoptimized metabolic environment is a cycle in which those therapies may be working less effectively than they could. The same inflammatory, insulin-driven, oxidatively stressed conditions that help cancer resist treatment in the laboratory do not pause during your infusion schedule. They are working against your treatment in real time, and waiting six months to address them means six months of treatment delivered into a body that is still feeding the fire. For patients who have completed treatment and been told they are in remission, the urgency is different but no less real. The highest-risk window for recurrence in many solid tumors falls within the first two to three years after treatment ends, though for some hormone-driven cancers the risk extends considerably longer. That window, whatever its length for your particular disease, is when the metabolic conditions that supported the original cancer either get corrected or quietly set the stage for what comes next. In both cases, the cost of waiting is not measured in inconvenience. It is measured in biology that continues to move in the wrong direction while no one is looking.
Dr. Thomas offers a structured consultation process designed to address the metabolic picture that standard oncology leaves unexamined. It includes a comprehensive lab order covering the cancer-linked biomarkers described above, a two-hour strategic session to transform the data into a personalized action plan, and a detailed written protocol covering dietary strategies, targeted supplementation, lifestyle modifications, and repurposed medications to discuss with your medical team.
One component of the consultation that patients consistently say is worth the cost on its own is the supplement review. Most cancer patients are taking multiple supplements, often based on internet research, well-meaning advice from friends, or recommendations from practitioners unfamiliar with their specific treatment regimen. In the review, Dr. Thomas identifies which supplements are genuinely helping, which are doing nothing, and which may be quietly undermining the effectiveness of their cancer treatment. For many patients, what they stop taking matters as much as what they start.
The consultation fee is $1,500 and is available either in-office or via telemedicine. For the depth of analysis, the time invested, and the level of personalized guidance you receive, patients consider it one of the best investments they have made in their cancer journey.
Personal guarantee from Dr. Thomas: “I want to make this decision as straightforward as possible. If, during our two-hour strategic session, I do not identify at least three actionable metabolic drivers worth addressing in your case, your consultation fee will be refunded in full. After 40 years of clinical practice, I have yet to review a set of these biomarkers on a cancer patient and not find meaningful targets for intervention, and I do not want the fee to stand between a patient and the information that could change the course of their care.”
Do not leave your metabolic health to chance. Download and complete our one-page Prospective Patient Form and email it to info@healthyandstrong.com or fax it to 888-481-6799. You can also call us directly at 352-729-0923. The sooner you uncover what is feeding the fire, the sooner you can start putting it out.
